FDA Approves Lusutrombopag for Thromocytopenia

On July 31, the Food and Drug Administration approved lusutrombopag(Mulpleta, Shionogi Inc.) for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. Approval was based on two randomized, double-blind, placebo-controlled trials (L-PLUS 1 and L-PLUS 2, NCT02389621) involving 312 patients with chronic liver disease and severe thrombocytopenia who were undergoing an invasive procedure and had a platelet count less than 50 x 109/L.

Read the full FDA announcement here.

Posted 8/1/2018